Celgene Corporation (CELG): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation ( CELG) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, Celgene Corporation rose $3.30 (2.5%) to $135.74 on average volume. Throughout the day, 2,170,028 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2,753,100 shares. The stock ranged in a price between $132.57-$136.85 after having opened the day at $132.97 as compared to the previous trading day's close of $132.44. Other companies within the Drugs industry that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 16.9%, ImmuCell Corporation ( ICCC), up 16.9%, XOMA ( XOMA), up 12.4% and ZIOPHARM Oncology ( ZIOP), up 11.0%.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $54.5 billion and is part of the health care sector. Shares are up 68.8% year to date as of the close of trading on Monday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Mast Therapeutics ( MSTX), down 44.1%, DARA Biosciences ( DARA), down 14.8%, Natural Alternatives International ( NAII), down 13.3% and iBio ( IBIO), down 9.8%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.